Background Nirmatrelvir/ritonavir was approved for use in high-risk outpatients with
coronavirus disease 2019 (COVID-19). However, patients with severe CKD were excluded …

Background Nirmatrelvir-ritonavir is currently not recommended in patients with an
estimated glomerular filtration rate (eGFR)< 30 mL/minute/1.73 m2. Methods To determine …

Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with
coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of …

Background Nirmatrelvir/ritonavir has been shown to reduce the risk of coronavirus disease
2019 (COVID-19)–related complications in patients at high risk for severe COVID-19 …

Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage …

Introduction The efficacy of nirmatrelvir-ritonavir (NR; Paxlovid, Pfizer, New York, NY) to
decrease the risk of progression to severe COVID-19 in high-risk patients has been …

As of December 2021, 18.2 million have died globally from coronavirus disease 2019
(COVID-19) due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and …

Thirteen patients with glomerular filtration rate (GFR)< 30 mL/minute (including 2 patients on
dialysis) presenting with mild COVID-19 were treated from December 2022 to April 2023 …

Nirmatrelvir coadministered with ritonavir is highly efficacious in reducing the risk of
coronavirus disease 2019 (COVID‐19) adverse outcomes among patients at increased risk …

Objectives Nirmatrelvir/ritonavir may cause a clinically relevant drug-drug interaction (DDI)
with immunosuppressive drugs, such as tacrolimus, which may condition the use of this …